DOCSLIB.ORG

Estonian Statistics on Medicines 2013 1/44

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Estonian Statistics on Medicines 2013 1/44 Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P) 3589,5 g 0,3 g 0,0255 A02BA03 Famotidine(O) 6 g 0,04 g 0,0003 A02BC Proton pump inhibitors 31,1637 A02BC01 Omeprazole(O) 205509,8 g 0,02 g 21,8912 A02BC02 Pantoprazole(O) 97564,46 g 0,04 g 5,1963 A02BC03 Lansoprazole(O) 21,42 g 0,03 g 0,0015 A02BC05 Esomeprazole(O) 54668,04 g 0,03 g 3,8822 A02BC05 Esomeprazole(P) 2710,8 g 0,03 g 0,1925 DRUGS FOR FUNCTIONAL GASTROINTESTINAL A03 6,0070 DISORDERS DRUGS FOR FUNCTIONAL GASTROINTESTINAL A03A 4,9530 DISORDERS A03AA Synthetic anticholinergics, esters with tertiary amino group 0,7177 A03AA04 Mebeverine(O) 101070 g 0,3 g 0,7177 A03AD Papaverine and derivatives 4,2353 A03AD01 Papaverine hydrochloride(P) 68 g 0,1 g 0,0014 A03AD01 Papaverine hydrochloride(P, V) 20 g 0,1 g 0,0004 A03AD02 Drotaverine(O) 193996,8 g 0,1 g 4,1330 A03AD02 Drotaverine(P) 4715 g 0,1 g 0,1004 A03AX Other drugs for functional gastrointestinal disorders A03AX13 Simeticone(O) 378946,8774 g A03B BELLADONNA AND DERIVATIVES, PLAIN 0,1152 A03BA Belladonna alkaloids, tertiary amines 0,0907 1/44 Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A03BA01 Atropine(O, P) 35,73 g 0,0015 g 0,0507 A03BA01 Atropine(P) 28,1 g 0,0015 g 0,0399 Belladonna alkaloids, semisynthetic, quaternary ammonium A03BB 0,0245 compounds A03BB01 Butylscopolamine(O) 83 g 0,06 g 0,0029 A03BB01 Butylscopolamine(P) 601 g 0,06 g 0,0213 A03BB01 Butylscopolamine(R) 6,1 g 0,06 g 0,0002 A03F PROPULSIVES 0,9389 A03FA Propulsives 0,9389 A03FA01 Metoclopramide(O) 10347,5 g 0,03 g 0,7348 A03FA01 Metoclopramide(P) 2225,8 g 0,03 g 0,1581 A03FA01 Metoclopramide(R) 0,55 g 0,03 g <0,0001 A03FA02 Cisapride(O) 4,2 g 0,03 g 0,0003 A03FA03 Domperidone(O) 642,6 g 0,03 g 0,0456 A03FA80 Itopride(O) 4 g A04 ANTIEMETICS AND ANTINAUSEANTS 0,1383 A04A ANTIEMETICS AND ANTINAUSEANTS 0,1383 A04AA Serotonin (5-HT3) antagonists 0,1254 A04AA01 Ondansetron(O) 43,68 g 0,016 g 0,0058 A04AA01 Ondansetron(P) 41,32 g 0,016 g 0,0055 A04AA02 Granisetron(O) 51,85 g 0,002 g 0,0552 A04AA02 Granisetron(P) 82,89 g 0,003 g 0,0589 A04AD Other antiemetics 0,0129 A04AD12 Aprepitant(O) 300,675 g 0,095 g 0,0067 A04AD81 Fosaprepitant(P) 273 g 0,095 g 0,0061 A05 BILE AND LIVER THERAPY 2,6052 A05A BILE THERAPY 0,4309 A05AA Bile acid preparations 0,4309 A05AA02 Ursodeoxycholic acid(O) 151700 g 0,75 g 0,4309 A05B LIVER THERAPY, LIPOTROPICS 2,1743 A05BA Liver therapy 2,1743 A05BA03 Silymarin(O) 3942080 pieces A05BA80 Essentsiaalsed fosfolipiidid(O) 3061770 pieces 3 pieces 2,1743 A05BA80 Essentsiaalsed fosfolipiidid(P) 3525 pieces A06 DRUGS FOR CONSTIPATION 13,9626 A06A DRUGS FOR CONSTIPATION 13,9626 A06AB Contact laxatives 7,0555 A06AB02 Bisacodyl(O) 16366,4 g 0,01 g 3,4867 A06AB02 Bisacodyl(R) 1018,3 g 0,01 g 0,2169 A06AB06 Senna glycosides(O) 17140 pieces 1 pieces 0,0365 A06AB08 Sodium picosulfate(O) 7780,8981 g 0,005 g 3,3153 A06AD Osmotically acting laxatives 6,2629 A06AD11 Lactulose(O) 19208421,6 g 6,7 g 6,1078 A06AD15 Macrogol(O) 728200 g 10 g 0,1551 Macrogol+Sodium citrate+Citric acid+Sodium A06AD80 600 ml chloride+Potassium chloride(O) Sodium sulphate, anhydrous+Potassium chloride+Sodium A06AD81 60836 pieces chloride+Macrogol+Sodium hydrogen carbonate(O) Macrogol+Potassium chloride+Sodium hydrogen A06AD84 18408 pieces carbonate+Sodium chloride(O) Sodium sulphate, anhydrous+magnesium sulfate A06AD85 13376 ml heptahydrate+Potassium sulphate(O) A06AG Enemas 0,6442 A06AG11 Laurilsulfate, incl. combinations+Sorbitol+Sodium citrate(R) 302380 pieces 1 pieces 0,6442 2/44 Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A06AX Other drugs for constipation A06AX01 Glycerol(R) 300 pieces ANTIDIARRHEALS, INTESTINAL A07 3,5777 ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07A INTESTINAL ANTIINFECTIVES <0,0001 A07AA Antibiotics <0,0001 A07AA02 Nystatin(O) 10000000 U 1500000 U <0,0001 A07B INTESTINAL ADSORBENTS 0,5031 A07BC Other intestinal adsorbents 0,5031 A07BC05 Diosmectidum(O) 2125560 g 9 g 0,5031 A07C ELECTROLYTES WITH CARBOHYDRATES A07CA Oral rehydration salt formulations Sodium chloride+Potassium chloride+Sodium A07CA80 38800 pieces citrate+Glucose(O) A07D ANTIPROPULSIVES 0,8627 A07DA Antipropulsives 0,8627 A07DA03 Loperamide(O) 4049,428 g 0,01 g 0,8627 A07E INTESTINAL ANTIINFLAMMATORY AGENTS 1,7814 A07EA Corticosteroids acting locally 0,0005 A07EA06 Budesonide(O) 2,1 g 0,009 g 0,0005 A07EA06 Budesonide(R) 1,939 g A07EB Antiallergic agents, excl.corticosteroids 0,0001 A07EB01 Cromoglicic acid(O) 40 g 0,8 g 0,0001 A07EC Aminosalicylic acid and similar agents 1,7808 A07EC01 Sulfasalazine(O) 870350 g 2 g 0,9271 A07EC02 Mesalazine(O) 554970 g 1,5 g 0,7882 A07EC02 Mesalazine(R) 46133 g 1,5 g 0,0655 A07F ANTIDIARRHEAL MICROORGANISMS 0,4304 A07FA Antidiarrheal microorganisms 0,4304 A07FA02 Saccharomyces boulardii(O) 202017,5 g 1 g 0,4304 A07X OTHER ANTIDIARRHEALS A07XA Other antidiarrheals A07XA04 Racecadotril(O) 994,76 g ANTIOBESITY PREPARATIONS, EXCL. DIET A08 0,0291 PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET A08A 0,0291 PRODUCTS A08AB Peripherally acting antiobesity products 0,0291 A08AB01 Orlistat(O) 4924,08 g 0,36 g 0,0291 A09 DIGESTIVES, INCL. ENZYMES 1,3290 A09A DIGESTIVES, INCL. ENZYMES 1,3290 A09AA Enzyme preparations 1,3288 A09AA02 Lipase+Amylase+Protease(O) 2494810 pieces 4 pieces 1,3288 A09AC Enzyme and acid preparations, combinations 0,0003 A09AC80 Pepsin+Betaine(O) 400 pieces 3 pieces 0,0003 A10 DRUGS USED IN DIABETES 56,1556 A10A INSULINS AND ANALOGUES 15,7880 A10AB Insulins and analogues for injection, fast-acting 5,9144 A10AB01 Insulin (human)(P) 1209000 U 40 U 0,0644 A10AB04 Insulin lispro(P) 23851500 U 40 U 1,2703 A10AB05 Insulin aspart(P) 74193000 U 40 U 3,9516 A10AB06 Insulin glulisine(P) 11793000 U 40 U 0,6281 A10AC Insulins and analogues for injection, intermediate-acting 0,2075 A10AC01 Insulin (human)(P) 3895500 U 40 U 0,2075 3/44 Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day Insulins and analogues for injection, intermediate-acting A10AD 2,0160 combined with fast-acting A10AD04 Insulin lispro(P) 13137000 U 40 U 0,6997 A10AD05 Insulin aspart(P) 24715500 U 40 U 1,3164 A10AE Insulins and analogues for injection, long-acting 7,6500 A10AE04 Insulin glargine(P) 75166500 U 40 U 4,0034 A10AE05 Insulin detemir(P) 68467500 U 40 U 3,6466 BLOOD GLUCOSE LOWERING DRUGS, EXCL. A10B 40,3676 INSULINS A10BA Biguanides 18,8116 A10BA02 Metformin(O) 17659980 g 2 g 18,8116 A10BB Sulfonamides, urea derivatives 17,3304 A10BB07 Glipizide(O) 2116,8 g 0,01 g 0,4510 A10BB09 Gliclazide(O) 270787,8 g 0,06 g 9,6149 A10BB12 Glimepiride(O) 6819,81 g 0,002 g 7,2645 A10BD Combinations of oral blood glucose lowering drugs 1,3893 A10BD07 Metformin+Sitagliptin(O) 1218728 pieces 2 pieces 1,2982 A10BD10 Metformin+Saxagliptin(O) 21060 pieces 2 pieces 0,0224 A10BD11 Metformin+Linagliptin(O) 64440 pieces 2 pieces 0,0686 A10BG Thiazolidinediones 0,1815 A10BG03 Pioglitazone(O) 2555,7 g 0,03 g 0,1815 A10BH Dipeptyl peptidase 4 (DPP-4) inhibitors 2,1917 A10BH01 Sitagliptin(O) 83330,1 g 0,1 g 1,7753 A10BH03 Saxagliptin(O) 59,85 g 5 mg 0,0255 A10BH05 Linagliptin(O) 917,55 g 5 mg 0,3910 A10BX Other blood glucose lowering drugs, excl. insulins 0,4631 A10BX04 Exenatide(P) 0,1449 g 0,286 mg 0,0011 A10BX07 Liraglutide(P) 260,244 g 1,2 mg 0,4620 A11 VITAMINS 14,1663 A11A MULTIVITAMINS, COMBINATIONS 1,4736 A11AA Multivitamins with minerals 1,4736 A11AA03 Multivitamins+Mineral elements(O) 691710 pieces 1 pieces 1,4736 A11B MULTIVITAMINS, PLAIN 0,0114 A11BA Multivitamins, plain 0,0114 A11BA80 Multivitamins(O) 53700 ml 10 ml 0,0114 VITAMIN A AND D, INCL.
Load more

Recommended publications
  • Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems
    pharmaceutics Review Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems Gemma Latter 1, Jeffrey E. Grice 2, Yousuf Mohammed 2 , Michael S. Roberts 2,3 and Heather A. E. Benson 1,* 1 School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth 6845, Australia; [email protected] 2 Therapeutics Research Group, The University of Queensland Diamantina Institute, School of Medicine, University of Queensland, Translational Research Institute, Brisbane 4109, Australia; jeff[email protected] (J.E.G.); [email protected] (Y.M.); [email protected] (M.S.R.) 3 School of Pharmacy and Medical Sciences, University of South Australia, Basil Hetzel Institute for Translational Health Research, Adelaide 5011, Australia * Correspondence: [email protected]; Tel.: +61-8-9266-2338 Received: 19 August 2019; Accepted: 17 September 2019; Published: 24 September 2019 Abstract: Acne vulgaris is a common inflammatory pilosebaceous condition that affects 80–90% of adolescents. Since the introduction of tretinoin over 40 years ago, topical retinoid products have been a mainstay of acne treatment. The retinoids are very effective in addressing multiple aspects of the acne pathology as they are comedolytic and anti-inflammatory, and do not contribute to antibiotic resistance or microbiome disturbance that can be associated with long-term antibiotic therapies that are a common alternative treatment. However, topical retinoids are associated with skin dryness, erythema and pain, and may exacerbate dermatitis or eczema. Thus, there is a clear need to target delivery of the retinoids to the pilosebaceous units to increase efficacy and minimise side effects in surrounding skin tissue.
    [Show full text]
  • Expert Review 2
    2021 Expert Committee on Selection and Use of Essential Medicines Application review I.1 Albendazole, mebendazole and praziquantel for the indication of treatment of (item number) taeniid cestode cysts Does the application adequately ☒ Yes address the issue of the public health ☐ need for the medicine? No ☐ Not applicable Comments: The larval stages of three taeniid cestode parasites, Echinococcus granulosus, Echinococcus multilocularis and Taenia solium, produce cysts in humans that are of medical relevance. The diseases caused by these parasitic cysts are called cystic echinococcosis (CE), alveolar echinococcosis (AE), and cysticercosis (being neurocysticercosis (NCC) the most common form) respectively, and they are recognised by WHO as neglected tropical diseases. NCC is mainly a disease of poverty that predominantly affects rural populations in Africa, Asia and Latin America. Access to diagnostic and treatment, to better manage epilepsy and other NCC is a challenge for the people affected in these communities due to the availability and costs of specialised diagnostic and care. Stigma and social discrimination also mean that many people try to “hide” the disease. Briefly summarize the role of the The only real options for treatment of CE are albendazole (ALB) and Mebendazole proposed medicine(s) relative to other (MEB). ALB is the drug of choice as it has better bioavailability. ALB is also preferred to therapeutic agents currently included in MEB, because MEB requires a higher dose and a higher pill burden, for example, an the Model List, or available in the adult patient would require 8 tablets/day of MEB compared with 2 tablets/day ALB. market. ALB and praziquantel ( PZQ) are the only drugs used for the antiparasitic treatment of NCC.
    [Show full text]
  • Cumulative Irritation Comparison of Adapalene Gel and Solution with 2 Tazarotene Gels and 3 Tretinoin Formulations
    THERAPEUTICS FOR THE CLINICIAN Cumulative Irritation Comparison of Adapalene Gel and Solution With 2 Tazarotene Gels and 3 Tretinoin Formulations Alan Greenspan, MD; Christian Loesche, MD; Nancy Vendetti; Kathleen Georgeian; Richard Gilbert, PhD; Michel Poncet, PhD; Michael D. Baker, BS; Pascale Soto, RPh Forty-two subjects with normal skin were enrolled gel 0.025%, and 1 discontinued adapalene in a single-center study to assess the cumula- gel 0.1%. None of the subjects discontinued use tive irritancy potential of adapalene (Differin® of the white petrolatum or the adapalene solu- gel 0.1% and Differin solution 0.1%) compared tion 0.1%. Adapalene gel and solution 0.1% with tazarotene (Tazorac® gels 0.05% and 0.1%), were statistically (PϽ.01) less irritating than tretinoin (Retin-A Micro® gel 0.1%, Avita® cream both tazarotene gels 0.1% and 0.05%, tretinoin 0.025%, and Avita gel 0.025%), and white petro- microsphere gel 0.1%, and tretinoin gel 0.025%, latum (negative control). All test materials were and they were not statistically different from applied randomly, under occlusion, to sites tretinoin gel 0.025%. located on either side of the midline— the mid Cutis. 2003;72:76-81. thoracic area of the subjects’ backs. All patches were applied daily, Monday through Friday, to dapalene (Differin®) is a naphthoic-acid the same sites, unless the degree of reaction to derivative with retinoid activity that is a test product or adhesive necessitated removal A effective in the treatment of mild to moder- (grade 3). ate acne vulgaris.1-4 Adapalene, in both gel and Thirty-eight of the 42 subjects (90.5%) com- cream formulations, at the marketed and approved pleted the study.
    [Show full text]
  • Topical Budesonide for Treating Giant Rectal Pseudopolyposis
    ANTICANCER RESEARCH 25: 2961-2964 (2005) Topical Budesonide for Treating Giant Rectal Pseudopolyposis CHARALAMPOS PILICHOS1, ATHENA PREZA1, MARIA DEMONAKOU2, DIMITRIOS KAPATSORIS1 and CONSTANTINOS BOURAS1 1First Department of Internal Medicine and 2Department of Pathology, Sismanogleion Hospital, Athens, Greece Abstract. Pseudopolyps are a frequent finding in the course of Case Report inflammatory bowel disease. They are non-neoplastic lesions resulting from a regenerative and healing process that leaves A 45-year-old male patient was admitted to our service in July inflamed colonic mucosa in polypoid configuration. Data about 2002 for acute rectal bleeding. All laboratory tests were their management is lacking. "Giant" pseudopolyps can be normal, except an increase of aminotransferases level (>10 N) mistaken for adenocarcinomas and, as they rarely regress with and a serological profile consistent with acute hepatitis B or a medical management alone, a surgical resection is often required. flare of chronic hepatitis B (HbsAg +, HbsAb –, HbeAg –, A case of giant pseudopolyposis treated non-surgically, in a patient HbeAb +, HbcAb-IgM +). The patient underwent lower with concomitant ulcerative colitis and chronic hepatitis B, is gastro-intestinal endoscopy and multiple biopsies were taken reported, representing a co-morbidity complicating an eventual from a bulky rectal mass lesion (Figure 1). Histological study conservative treatment. The clinical implementation of topical revealed alterations compatible with inflammatory bowel budesonide was originally tested, resulting in clinical, endoscopic disease (IBD) with no dysplasia (Figure 2). Because of the and histological remission. Budesonide seems a promising therapy atypical macroscopic features and the high suspicion of rectal for IBD, particularly when a comorbidity with viral hepatitis exist.
    [Show full text]
  • New Insights Into the Effect of Amorolfine Nail Lacquer
    Review article New insights into the effect of amorolfine nail lacquer C. Flagothier, C. Pie´ rard-Franchimont and G. E. Pie´ rard Department of Dermatopathology, University Hospital of Lie`ge, Lie`ge, Belgium Summary Despite improvements in antifungal strategies, the outcome of treating onychomycoses often remains uncertain. Several factors account for treatment failure, of which the pharmacokinetics and pharmacodynamics of the antifungal are of importance. The taxonomic nature and ungual location of the fungus cannot be neglected, besides the type of nail and its growth rate. In addition, the biological cycle of the fungus and the metabolic activity of the pathogen likely play a marked influence in drug response. The presence of natural antimicrobial peptides in the nail is also probably a key feature controlling the cure rates. There are many outstanding publications that cover the full spectrum of the field. The purpose of this review is to put in perspective some facets of activity of the topical treatment using amorolfine nail laquer. The antifungal activity of the drug is likely less pronounced in onychomycosis than that expected from conventional in vitro studies. However, the nail laquer formulation should reduce the propensity to form antifungal-resistant spores and limit the risk of reinfection. Key words: amorolfine, antifungal, fungus, onychomycosis, spore. Topical treatments are often considered to be less Introduction efficacious than current oral treatments. However, some During the last 2 decades, the efficacy of treating topical formulations may provide effects that cannot be onychomycoses has been considerably improved by achieved by other treatments. In discussing the treat- the introduction of new generations of potent antifun- ment of onychomycosis, it should not be forgotten that gals.
    [Show full text]
  • Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D
    PRACTICE PARAMETERS Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D. • Scott R. Steele, M.D. • Mika Varma, M.D. • Sharon Dykes, M.D. Robert Cima, M.D. • W. Donald Buie, M.D. • Janice Rafferty, M.D. Prepared by the Standards Practice Task Force of the American Society of Colon and Rectal Surgeons he American Society of Colon and Rectal Surgeons the most common surgical indication for UC. Whether is dedicated to assuring high-quality patient care it is secondary to an inability to control symptoms, poor Tby advancing the science, prevention, and manage- quality of life, risks/side effects of chronic medical therapy ment of disorders and diseases of the colon, rectum, and (especially long-term corticosteroids), noncompliance, or anus. The Standards Committee is composed of Society growth failure, patients may opt for surgery in the elective members who are chosen because they have demonstrat- or semielective setting.3 Complete removal of all the poten- ed expertise in the specialty of colon and rectal surgery. tial disease-bearing tissue is theoretically curative in UC. This Committee was created to lead international efforts Operative options include an abdominal colectomy or total in defining quality care for conditions related to the co- proctocolectomy with either a permanent end ileostomy or lon, rectum, and anus. This is accompanied by develop- surgical construction of a “new” rectum through an IPAA ing Clinical Practice Guidelines based on the best available that restores GI continuity.4,5 All these procedures may evidence. These guidelines are inclusive, and not prescrip- be performed by using open or minimally invasive tech- tive.
    [Show full text]
  • More Than Expectorant: New Scientific Data on Ambroxol in the Context of the Treatment of Bronchopulmonary Diseases
    Mini Review iMedPub Journals Journal of Intensive and Critical Care 2017 www.imedpub.com ISSN 2471-8505 Vol. 3 No. 3: 37 DOI: 10.21767/2471-8505.100096 More than Expectorant: New Scientific Data Manuel Plomer1* and 2 on Ambroxol in the Context of the Treatment Justus de Zeeuw of Bronchopulmonary Diseases 1 Medical Affairs CHC Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, D-65926, Frankfurt am Main, Deutschland, German Abstract 2 Medical Specialist for Internal Medicine, Pneumology and Sleep Medicine, Background:Ambroxol has been established for decades in the treatment of Cologne, Germany, German acute and chronic respiratory diseases. A reassessment of the benefit-risk was conducted recently. Objective: What new scientific data, relevant for the treatment of *Corresponding author: bronchopulmonary diseases, were published in the last decade? Dr. Manuel Plomer Method: Systematic literature search via http://www.pubmed.gov with the search term “ambroxol”, covering the publication period from 2006 to 2015. Non- [email protected] relevant publications were excluded manually. Medical Manager, Medical Affairs CHC Results: 64 relevant publications could be identified covering both, clinical and Germany, Sanofi-Aventis Deutschland GmbH, preclinical research. Industriepark Höchst, D-65926 Frankfurt am Conclusion: The traditional indication of ambroxol as an expectorant is confirmed Main, Germany. but new results revealed a better understanding of the various mechanisms of action of ambroxol and the benefits for special patient populations. The Tel: 49 69 305 36803 available data suggest the use of ambroxol as an adjuvant in anti-infective therapy, particularly in case of infections with biofilm-producing pathogens. Lung- protective properties are discussed in both infants and severely ill adult patients.
    [Show full text]
  • ALBENDAZOLE (Extrapolation to All Ruminants)
    European Medicines Agency Veterinary Medicines and Inspections EMEA/MRL/865/03-FINAL June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE ALBENDAZOLE (Extrapolation to all ruminants) SUMMARY REPORT (3) 1. Albendazole is a benzimidazole carbamate, used for the treatment of gastrointestinal infestations with roundworms, lungworms and tapeworms and adult flukes of Fasciola hepatica. Albendazole is currently entered into Annex I of Council Regulation (EEC) No. 2377/90 in accordance with the following table: Pharmacologically Marker residue Animal MRLs Target Other active substance(s) species tissues provisions Albendazole Sum of albendazole Bovine, 100 µg/kg Muscle sulphoxide, ovine 100 µg/kg Fat albendazole sulphone 1000 µg/kg Liver and albendazole 2- 500 µg/kg Kidney amino sulphone 100 µg/kg Milk expressed as albendazole 2. In reviewing the availability of endo- and ectoparasiticides for sheep and goats, albendazole was considered for extrapolation from bovine and ovine species to all ruminants. The considerations and criteria leading to the identification of albendazole are described in the Position Paper Regarding Availability of Veterinary Medicines – Extrapolation of MRLs (EMEA/CVMP/457/03-FINAL). 3. The scientific justification for this extrapolation was assessed in accordance with the Notes for Guidance on Risk Analysis Approach for Residues of Veterinary Medicinal Products in Food of Animal Origin (EMEA/CVMP/187/00-FINAL) and on the Establishment of Maximum Residue Limits for Minor Animal Species (EMEA/CVMP/153a/97-FINAL). 4. In setting the ADI in the original assessment of albendazole, the data summarised on the paragraphs below were considered. 5. The mode of action of albendazole is by binding strongly with the tubulin in the cells of nematodes.
    [Show full text]
  • Australian Public Assessment Report for Abatacept (Rch)
    Australian Public Assessment Report for Abatacept (rch) Proprietary Product Name: Orencia Sponsor: Bristol-Myers Squibb Australia Pty Ltd June 2011 About the Therapeutic Goods Administration (TGA) · The TGA is a division of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. · TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website. About AusPARs · An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • European Journal of Scientific Exploration Vol 3 №2 2020
    EUROPEAN JOURNAL OF SCIENTIFIC EXPLORATION VOL 3 №2 2020 Determination of Oligomer Content in Benzonatate Drug Substance by HPLC Lakshmi Narasimha Rao Katakam 1 Santhosh Kumar Ettaboina 2 Thirupathi Dongala 2 1Saptalis Pharmaceuticals LLC, New York, USA 2Aurex Pharmaceuticals Inc, East Windsor, USA Abstract. A reverse-phase liquid chromatographic method has developed and validated to determine oligomer content in Benzonatate Drug substances. This method has a separation of relatively few monomer units, which constitutes an oligomer with a minimum adequate chromatographic resolution of 1.0 from each of the subject component peaks. The separation achieved using Phenomenex Luna C18 (250 X 4.6 mm) 5 µm column at a flow rate of 1.0 ml/min with an isocratic elution method. The mobile phase consisting of 0.25% Ammonium formate buffer and methanol in the ratio 350:650 (v/v), respectively. The Oligomer compounds detection carried out at UV 310 nm, and the LC method validated as per the current ICH Q2 guidelines. The method is effectively validated and proved to be precise, specific, linear, robust, and rugged to quantitate oligomer content in Benzonatate drug substance. Key words: benzonatate (BNZ), oligomers, HPLC, method validation. Introduction Benzonatate (BNZ) is an oral antitussive drug used to relieve and suppress cough in patients older than ten years of age (Oligomer Wikipedia, 2020). Currently, BNZ is the only non-narcotic antitussive available as a prescription drug. The chemical structure resembles that of the anesthetic agents in the para-amino-benzoic acid class (such as procaine and tetracaine), BNZ exhibits anesthetic or numbing action. BNZ also inhibits the transmission of impulses of the cough reflex in the medulla's vagal nuclei (Tessalon, 2020).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]